论文部分内容阅读
目的:探讨蛋白酶激活受体-2(PAR-2)及基质金属蛋白酶-2(MMP-2)在正常宫颈组织、宫颈原位癌、宫颈浸润癌组织中的表达及临床意义。方法:采用免疫组化SP法分别检测PAR-2、MMP-2在15例正常宫颈组织,20例宫颈原位癌组织,70例宫颈浸润癌组织中的表达。结果:PAR-2及MMP-2在宫颈浸润癌组织中阳性表达率分别为45.71%及71.43%,明显高于宫颈原位癌及正常宫颈组织(P<0.01),PAR-2在宫颈癌盆腔淋巴结转移组和未转移组中的阳性表达率分别为72.41%和26.83%,MMP-2的阳性表达率分别为93.10%和56.10%,两组比较差异有统计学意义,P<0.01。结论:PAR-2及MMP-2与宫颈癌的侵袭和淋巴结转移密切相关。
Objective: To investigate the expression and clinical significance of PAR-2 and MMP-2 in normal cervical tissue, cervical carcinoma in situ and invasive cervical carcinoma. Methods: The expressions of PAR-2 and MMP-2 in 15 cases of normal cervical tissue, 20 cases of cervical carcinoma in situ and 70 cases of invasive cervical carcinoma were detected by immunohistochemical SP method. Results: The positive rates of PAR-2 and MMP-2 in invasive cervical carcinoma were 45.71% and 71.43%, respectively, which were significantly higher than those in cervical carcinoma and normal cervical tissue (P <0.01) The positive expression rates of MMP-2 and MMP-2 in lymph node metastasis group and non-metastasis group were 72.41% and 26.83%, respectively. The positive expression rate of MMP-2 was 93.10% and 56.10% respectively. There was significant difference between the two groups (P <0.01). Conclusion: PAR-2 and MMP-2 are closely related to the invasion and lymph node metastasis of cervical cancer.